Nintedanib vs Pirfenidone for IPF: Which Is Better?

Research-informed explainer — last updated April 12, 2026

Nintedanib (Ofev) and pirfenidone (Esbriet) are the two FDA-approved antifibrotic medications for idiopathic pulmonary fibrosis (IPF). Both slow the rate of lung function decline by roughly half compared to no treatment — but neither stops progression or reverses scarring, and they work through different molecular mechanisms with distinct side effect profiles. Research has not shown one to be clearly superior; the choice between them typically comes down to tolerability, comorbidities, and patient preference.

This comparison draws on the underlying science of fibrosis, the clinical trial evidence for each drug, and diagnostic context from pulmonologists at Northwestern, Vanderbilt, and Cleveland Clinic who have worked across interstitial lung disease, pulmonary pathology, and lung disease evaluation [1][2][3]. Understanding what drives IPF — and what these drugs actually target — helps make sense of how they differ.

What's the difference?

Nintedanib is a tyrosine kinase inhibitor. It blocks several growth factor receptors, including those involved in the fibroblast growth factor (FGF), platelet-derived growth factor (PDGF), and vascular endothelial growth factor (VEGF) signaling pathways. These pathways drive abnormal fibroblast activation and scar tissue deposition in the lung. The biology of fibrosis involves cascades like TGF-beta signaling — where mitochondrial reactive oxygen species act as critical intermediaries that drive fibroblasts toward excessive scar production [1]. Nintedanib interrupts several of the downstream amplifying signals in that process.

Pirfenidone has a broader and less completely understood mechanism. It inhibits TGF-beta and other profibrotic cytokines, reduces fibroblast proliferation and migration, and has anti-inflammatory properties. Its exact molecular targets are less precisely defined than nintedanib's, but its effects on multiple fibrotic pathways are well established in clinical trials.

At a glance

What the major trials showed

Both drugs earned FDA approval in 2014 based on randomized controlled trials measuring forced vital capacity (FVC) — the amount of air exhaled in a full breath — as the primary outcome. FVC decline tracks disease progression in IPF and is accepted as a clinically meaningful endpoint.

Nintedanib was evaluated in two large Phase III trials called INPULSIS-1 and INPULSIS-2, each enrolling more than 500 patients. In both trials, the annual rate of FVC decline was approximately 125 mL per year in the placebo group; nintedanib reduced this to about 115 mL per year — cutting the rate of decline roughly in half. Diarrhea occurred in about 60% of nintedanib-treated patients, and about 5% had liver enzyme elevations requiring dose reduction or discontinuation.

Pirfenidone was studied in the CAPACITY trials (two trials combined) and later in the ASCEND trial, which was specifically designed to meet FDA requirements after initial regulatory uncertainty. ASCEND enrolled 555 patients and showed that pirfenidone reduced FVC decline by approximately half compared to placebo. The side effect profile differs: gastrointestinal upset is common but usually less severe than nintedanib-associated diarrhea, and photosensitivity — sun sensitivity that can cause rash or sunburn with minimal exposure — is a distinctive side effect that requires sun protection strategies.

Neither drug has been shown to reduce mortality as a primary endpoint in a randomized trial, though observational data and meta-analyses suggest that antifibrotic treatment is associated with longer survival compared to no treatment.

How the choice is typically made

There is no head-to-head randomized trial comparing nintedanib and pirfenidone. Both drugs slow disease at roughly equivalent rates. Clinicians — typically ILD specialists or pulmonologists with IPF experience — generally base the choice on:

• Side effect tolerance: Patients with pre-existing diarrhea, bowel disease, or who are very physically active may prefer pirfenidone. Those with significant sun exposure or who work outdoors may prefer nintedanib.
• Comorbidities: Nintedanib requires monitoring of liver function tests; patients with pre-existing liver disease need caution. Pirfenidone can cause fatigue that may matter more in patients already debilitated.
• Coronary artery disease or bleeding risk: Nintedanib carries some antiplatelet effects given its VEGF pathway targeting. This may be relevant in patients on anticoagulants or with recent vascular procedures.
• Extended indications: Nintedanib has been approved for additional fibrotic lung diseases beyond IPF — including systemic sclerosis-associated ILD and other progressive fibrotic ILDs — giving it broader coverage in patients with connective tissue disease-related lung involvement [2].
• Patient preference and pill burden: Three-times-daily dosing with pirfenidone versus twice-daily with nintedanib can affect adherence.

Getting the right diagnosis first

Before starting either drug, the diagnosis of IPF needs to be confirmed — and that is not always straightforward. IPF is a specific histological and radiological pattern (usual interstitial pneumonia, or UIP) that must be distinguished from other interstitial lung diseases with different causes and different treatments. Research on UIP patterns in connective tissue disease-associated ILD, for example, shows that the same radiological pattern can carry different prognoses depending on the underlying cause — patients with rheumatoid arthritis-associated UIP have meaningfully shorter survival (median 3.2 years) than those without UIP [2], which shapes both diagnostic thinking and urgency of treatment.

Diagnosing the UIP pattern typically requires high-resolution CT scanning. In cases where CT is not definitive, tissue biopsy — either surgical or via transbronchial cryobiopsy — is used. Transbronchial cryobiopsy is a less invasive alternative to surgical lung biopsy for diagnosing diffuse parenchymal lung diseases, and expert consensus supports its use at centers with appropriate experience and standardization [3]. Getting the right tissue sample and the right pathological interpretation determines whether IPF is the correct diagnosis and whether antifibrotic therapy is appropriate.

Because IPF can overlap radiologically with other conditions, including early lung cancer in older smokers, comprehensive lung evaluation — including lung nodule surveillance where indicated — is often part of the same workup [4][5][6].

What's changing: sequential therapy and combination approaches

Research is ongoing into whether switching from one antifibrotic to another at the time of disease progression provides benefit. Some centers offer sequential therapy — moving from pirfenidone to nintedanib or vice versa — when a patient experiences intolerable side effects or apparent disease breakthrough, though controlled trial data on this approach are limited.

The bigger shift in IPF management is the expanding use of nintedanib beyond classic IPF to progressive fibrotic ILDs more broadly. Clinical trials have now established that the same pattern of progressive FVC decline can occur in patients with hypersensitivity pneumonitis, connective tissue disease-related ILD, and unclassifiable ILD, and that nintedanib slows progression in these groups as well. This has changed how pulmonologists categorize and approach patients whose lungs are scarring progressively regardless of underlying cause.

Lung transplant evaluation — particularly single lung transplant — remains the only treatment that extends survival substantially for IPF patients with advanced disease, and referral timing relative to antifibrotic therapy is an active area of discussion in ILD programs.

Questions to ask your doctor

• Is my diagnosis definitively IPF, or is there uncertainty about the pattern? What would change that answer?
• Has my care been reviewed by a multidisciplinary team including an ILD specialist, thoracic radiologist, and pathologist?
• Which side effects am I most likely to notice on each drug based on my other health conditions and lifestyle?
• How will we know if the treatment is working, and how often will you check my FVC?
• At what point would you consider switching from one drug to the other, and under what circumstances would you consider listing me for lung transplant evaluation?
• Are there clinical trials available that I would be eligible for?

The bottom line

Nintedanib and pirfenidone reduce the rate of IPF progression by a similar magnitude — roughly half the annual FVC decline seen without treatment. Neither is clearly superior in efficacy; the difference lies in their mechanisms, side effect profiles, and indications. Nintedanib has broader approval across fibrotic lung diseases. Pirfenidone requires strict sun protection. The decision between them is best made with a pulmonologist or ILD specialist who knows your complete medical history, can confirm the IPF diagnosis, and can monitor treatment response over time.